Advertisement

Terminal Transferase and Adenosine Deaminase Activities in Human Neoplasia: Their Role in Modulating Cancer Treatment

  • P. S. Sarin
  • A. Thornton
  • D. Sun
Part of the NATO ASI Series book series (NSSA, volume 120)

Abstract

Terminal deoxynucleotidyl transferase (TdT) and adenosine deaminase (ADA) are two enzyme markers that have been exstensively utilized to define the stage of the disease and the cell types involved in human leukemia B cell proliferation and severe combined immune deficiency syndrome (SCID). The use of these biological markers has been very useful in selecting treatment protocols for patients with leukemia/lymphoma and SCID.

Keywords

Acute Lymphoblastic Leukemia Chronic Lymphocytic Leukemia Chronic Myelogenous Leukemia Adenosine Deaminase Blast Crisis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    P.S. Sarin, Terminal transferase as a biological marker for Lyman leukemia, in: “Recent Advances in Cancer Research” (R.C. Gallo, edt.), CRC Press, Cleveland, Vol. I, p. 131 (1977).Google Scholar
  2. 2.
    F.J. Bollum, Terminal deoxynucleotidyl transferase as a hematopoietic cell marker, Blood, 54: 1203 (1979).PubMedGoogle Scholar
  3. 3.
    J.S. Krakow, S. Coustogeorgopoulos, and E.S. Cannelakis, Incorporation of deoxyribonucleotides into terminal positions of DNA, Biochem. Biophys. Res. Comm., 5: 477 (1961).CrossRefGoogle Scholar
  4. 4.
    F.J. Bollum, Oligodeoxyribonucleotide primed reaction catalyzed by calf thymus polymerase, J. Biol. Chem., 237: 1945 (1962).PubMedGoogle Scholar
  5. 5.
    R.McCaffrey, D.F. Smolar, and D. Baltimore, Terminal deoxynucleotidyl transferase in a case of childhood acute lymphoblastic leukemia, Proc. Natl. Acad. Sci. USA, 70: 521 (1973).PubMedCrossRefGoogle Scholar
  6. 6.
    P.S. Sarin, P.N. Anderson, and R.C. Gallo, Terminal deoxynucleotidyl transferase activities in human Blood leukocytes and lymphoblast cell lines. High levels in lymphoblast cell lines and in blast cells of some patients with chronic myelogenous leukemia in acute phase, Blood, 47: 11 (1976).PubMedGoogle Scholar
  7. 7.
    M.S. Coleman, M.F. Greenwood, J.J. Hutton, F.J. Bollum, B. Lampkin, and P. Holland, Serial observations on terminal deoxynucleotidyl transferase activity and lymphoblast surface markers in acute lymphoblastic leukemia, Cancer Res., 36: 120 (1976).PubMedGoogle Scholar
  8. 8.
    G.Janossy, F.J. Bollum, K.R. Bradstock, A. McMichael, N. Rapson, and M.F. Greaves, Terminal transferase positive human bone marrow cells exhibit the antigenic phenotype of common acute lymphoblastic leukemia, J. Immunol., 123: 1525 (1979).PubMedGoogle Scholar
  9. 9.
    P.S. Sarin, and R.C. Gallo, Terminal deoxynucleotidyl transferase as a biological marker for human leukemia, in: “Modern Trends in Human Leukemia” (R. Noth, Ed.) J. F. Lehmann’s Verlag, Munich, Vol. 2, p. 491 (1971).Google Scholar
  10. 10.
    P.H. Wiernik, L.S. Edwards, and P.S. Sarin, Marrow terminal deoxynucleotidyl transferase activity in adult acute leukemia, Hämatol. Bluttransfusion, 23: 125 (1979).Google Scholar
  11. 11.
    P.S Sarin, and R.C. Gallo, Terminal deoxynucleotidyl transferase in chronic myelogenous leukemia, J. Biol. Chem., 249: 8051 (1974).PubMedGoogle Scholar
  12. 12.
    J.J. Hutton, and M.S. Coleman, Terminal deoxynucleotidyl transferase measurements in the differential diagnosis of adult leukemias. Brit. J. Haematol., 34: 447 (1976).CrossRefGoogle Scholar
  13. 13.
    R.McCaffrey, T. Harrison, R. Parkman, and D. Baltimore, Terminal deoxynucleotidyl transferase activity in human leukemia cells and in normal human thymocytes, New Engl. J. med., 292: 775 (1975).Google Scholar
  14. 14.
    M.M. Oken, P.S. Sarin, R.C. Gallo, J.G. Johnson, B.J. Gormus, R.E. Rydell, and M.E. Kaplan, Terminal transferase levels in chronic myelogenous leukemia in blast crisis and in remission, Leuk. Res., 2: 173 (1978).Google Scholar
  15. 15.
    D.D. Ross, P.H. Wiernik, P.S. Sarin, and J. Whang-Peng, Loss of terminal deoxynucleotidyl transferase (TdT) activity as a predictor of emergence of resistance to chemotherapy in a case of chronic myelogenous leukemia in blast crisis, Cancer, 44: 1566 (1979).PubMedCrossRefGoogle Scholar
  16. 16.
    P.S. Sarin, and R.C. Gallo, Characterization of terminal deoxynucleotidyl transferase in a cell line (8402) derived from a patient with acute lymphoblastic leukemia, Biochem. Biophys. Res. Comm., 65: 673 (1975).CrossRefGoogle Scholar
  17. 17.
    B.Srivastava, and J. Minowada, Terminal deoxynucleotidyl transferase in a cell line (Molt-4) derived from the peripheral Blood of a patient with acute lymphoblastic leukemia, Biochem. Bioph s. Res. Commun., 51: 529 (1973).Google Scholar
  18. 18.
    P.S. Sarin, M. Virmani, and B. Friedman, Terminal transferase in acute lymphoblastic leukemia in gibbons, Biochim. Biophys. Acta, 608: 62 (1980).Google Scholar
  19. 19.
    M.S. Coleman, J.J. Hutton, P.D. Simone, and F.J. Bollum, Terminal deoxyribonucleotidyl transferase in human leukemia, Proc. Natl. Acad. Sci. USA, 71: 4404 (1974).PubMedCrossRefGoogle Scholar
  20. 20.
    S.L. Marcus, S.W. smith, C.I. Jarowski, and M.J. Modak, Terminal deoxyribonucleotidyl transferase activity in acute undifferentiated leukemia, Biochem. Biophys. Res. Commun., 70: 37 (1976).CrossRefGoogle Scholar
  21. 21.
    I.P. Brusamolino, E.P. Alessandrino, A.I. Servassi, U. Bertazzoni, and C. Bernasconi, Terminal deoxynucleotidyl transferase positive acute leukemias evolving from a myelodysplastic syndrome, Am. J. Hematol., 20: 187 (1985).PubMedCrossRefGoogle Scholar
  22. 22.
    P.S. Sarin, M. Virmani, and R.C. Gallo, Enrichment of cell populations containing terminal transferase activity by free flow electrophoresis, Int. J. Cancer, 29: 507 (1982).CrossRefGoogle Scholar
  23. 23.
    R.D. Barr, P.S. Sarin, and S. Perry, Terminal transferase in human bone marrow lymphocytes, Lancet, 1: 508 (1976).PubMedCrossRefGoogle Scholar
  24. 24.
    F.J. Bollum, Antibody to terminal deoxynucleotidyl transferase, Proc. Natl. Acac. Sci. USA, 72: 4119 (1975).CrossRefGoogle Scholar
  25. 25.
    F.J. Bollum, Terminal deoxynucleotidyl transferase as a hematopoietic cell marker, Blood, 54: 1203 (1979).PubMedGoogle Scholar
  26. 26.
    P.C. Kung, P.D. Gottlieb, and D. Baltimore, Terminal deoxynucleotidyl transferase. Serological studies and radioimmunoassay, J. Biol. Chem., 251: 2399 (1976).PubMedGoogle Scholar
  27. 27.
    S.M. Marks, D. Baltimore, and R.P. McCaffrey, Terminal transferase as a predictor of initial responsiveness to vincristine and prednisone in blastic chronic myelogenous leukemia, New Engl. J. med., 298: 812 (1978).Google Scholar
  28. 28.
    R.McCaffrey, A. Lillquist, S. Sallan, E. Cohen, and M. Osband, Clinical utility of leukemia cell terminal transferase measurements, Cancer Res., 41: 4814 (1981).PubMedGoogle Scholar
  29. 29.
    G.Janossy, R.K. Woodruff, M.J. Pippara, H.G. Prentice, A.V. Hoffbrand, A. Paxton, A. Lister, T.A. Brunch, and M.F. Greaves, Relation of lymphoid phenotype and response to chemotherapy incorporating vincristine-prednisolone in the acute phase of Ph-1 positive leukemia, Cancer, 43: 426 (1979).PubMedCrossRefGoogle Scholar
  30. 30.
    K.Ono, Y. Iwata, H. Nakamura, and A. Matsukage, Selective inhibition of terminal deoxynucleotidyl transferase by diadenosine tetraphosphate, Biochem. Biophys. Res. Commun., 95: 34 (1980).PubMedCrossRefGoogle Scholar
  31. 31.
    W.E.G. Müller, R.K. Zahn, and J. Arendes, Differential mode of inhibition of terminal deoxynucleotidyl transferase by 3°-dATP, ATP, ß-araATP and a-araATP, FEES Letters, 94: 47 (1978).CrossRefGoogle Scholar
  32. 32.
    R.A. DiCioccio, and B.I.S. Srivastava, Inhibition of deoxynucleotide polymerizing enzyme activities of human cells and of simian sarcoma virus by heparin, Cancer Res., 38: 2401 (1978).PubMedGoogle Scholar
  33. 33.
    M.S. Coleman, and M.R. Deibel, Terminal deoxynucleotidyl transferase, in: “Enzymes of Nucleic Acid Synthesis and Modification” (S. Jacob, Ed.) Academic Press, New York, Vol. 1, p. 93 (1983).Google Scholar
  34. 34.
    S.Capitani, G. Mazzotti, S. Papa, P. Santi, and F.A. Manzoli, Effect of phospholipid vesicles on the activity of terminal transferase, Biochem. Biophys. Res. Comm., 89: 1206 (1979).PubMedCrossRefGoogle Scholar
  35. 35.
    R.McCaffrey, R. Bell, and A. Lillquist, Selective killing of leukemia cells by inhibition of TdT, Hematol. Bluttransf., 28: 24 (1983).Google Scholar
  36. 36.
    M.J. Modak, Biochemistry of terminal deoxynucleotidyl transferase: Mechanism of inhibition by adenosine 5’ triphosphate, Biochemistry, 17: 3116 (1978).PubMedCrossRefGoogle Scholar
  37. 37.
    M.S. Coleman, J. Donofrio, J.J. Hutton, I. Hahn, A. Daoud, B.J. Lampkin, and J. Dynminski, Identification and quantification of adenine deoxynucleotides in erythrocytes of a patient with adenosine deaminase deficiency and severe combined immunodeficiency, J. Biol. Chem., 253: 1619 (1978).PubMedGoogle Scholar
  38. 38.
    E.R. Giblett, J.E. Anderson, F. Cohen, B. Pollara, and H.J. Mewissen, Adenosine deaminase deficiency in two patients with severely impaired cellular immunity, Lancet, 2: 1067 (1972).PubMedCrossRefGoogle Scholar
  39. 39.
    R.Bell, R.P. Agarwal, A. Lillquist, and R. McCaffrey, Biochemical markers in neoplastic lymphoid cells, in: “Immunology of the lymphomas” (S.B. Sutcliffe, Ed.), CRC Press, Boca Raton, Florida, p. 154 (1985).Google Scholar
  40. 40.
    A.Cohen, R. Hirschhorn, S.D. Horowitz, A. Rubinstein, S.H. Polmar, R. Hong, and D.W. Martin, Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency, Proc. Natl. Acad. Sci. USA, 75: 472 (1978).PubMedCrossRefGoogle Scholar
  41. 41.
    J.F. Smyth, and K.R. Harrap, Adenosine deaminase activity in leukemia, Brit. J. Cancer, 31: 544 (1975).CrossRefGoogle Scholar
  42. 42.
    H.Nishihara, S. Ishikawa, K. Shinkai, and H. Akedo, Multiple forms of human adenosine deaminase, Biochim. Biophys. Acta, 302: 429 (1973).PubMedGoogle Scholar
  43. 43.
    C.Sufrin, G.L. Trisch, A. Mittleman, and G.P. Murphy, Adenosine deaminase activity in patients with carcinoma of the bladder, J. Urol., 119: 343 (1978).PubMedGoogle Scholar
  44. 44.
    L.H. Koehler, and E.J. Benz, Serum adenosine deaminase: Methodology and clinical application, Clin. Chem., 8: 133 (1962).PubMedGoogle Scholar
  45. 45.
    G.L. Tritsch, and J. Minowada, Differences in purinic metabolizing activities in human leukemia T cell, B cell and ALL cell lines, J. Natl. Cancer Inst., 60: 1301 (1978).PubMedGoogle Scholar
  46. 46.
    E.Brusamolino, P. Isernia, M. Lazzarino, I. Scovassi, U. Bertazzoni, and C. Bernasconi, Clinical utility of terminal deoxynucleotidyl transferase and adenosine deaminase determinations in adult leukemia with a lymphoid phenotype, J. Clin. Oncol., 2: 871 (1984).PubMedGoogle Scholar
  47. 47.
    P.E. Daddona, and W.N. Kelley, Human adenosine deaminase. Purification and subunit structure, J. Biol. Chem., 252: 110 (1977).PubMedGoogle Scholar
  48. 48.
    D.A. Wiginton, M.S. Coleman, and J.J. Hutton, Purification, characterization and radioimmunoassay of adenosine deaminase from human leukemic granulocytes, Biochem. J., 195: 389 (1981).PubMedGoogle Scholar
  49. 49.
    D.A. Wiginton, G.S. Adrian, R.L. Friedman, D.P. Suttle, and J.J. Hutton, Cloning of cDNA sequences of human adenosine deaminase, Proc. Natl. Acad. Sci. USA, 80: 7481 (1983).PubMedCrossRefGoogle Scholar
  50. 50.
    D.Valerio, M.G. Duvestyn, P.M. Khan, A.G. Van Kessel, A.D. Waard, and A.J.V. Eb, Isolation of cDNA clones for human adenosine deaminase, Gene, 25: 231 (1983).PubMedCrossRefGoogle Scholar
  51. 51.
    R.Agarwal, Inhibitors of adenosine deaminase, Pharmacol. Therap., 17: 399 (1982).CrossRefGoogle Scholar
  52. 52.
    M.S. Coleman, Selective enzyme inhibitors as antileukemic agents, Bioscience, 33: 707 (1983).CrossRefGoogle Scholar
  53. 53.
    J.F. Smythe, M.M. Chassin, K.R. Harrap, R.H. Adamson, and D.G. Johns, 2-Deoxycoformycin phase I clinical trial and clinical pharmacology, Proc. Am. Assoc. Cancer Res., 20: 47 (1979).Google Scholar
  54. 54.
    M.Grever, J. Miser, S. Balcerzak, and J. Neidhart, Ablation of adenosine deaminase activity by deoxycoformycin induces cell lysis in refractory leukemia, Proc. Am. Assoc. Cancer Res., 21: 335 (1980).Google Scholar
  55. 55.
    D.G. Poplack, S.E. Sallan, G. Rivera, J. Holcenberg, S.B. Murphy, J. Blatt, J.M. Lipton, P. Venner, D.L. Glaubiger, R. Ungerleider, and D. Johns, Phase I Study of 2’-deoxycoformycin in acute lymphoblastic leukemia, Cancer Res., 41: 3343 (1981).PubMedGoogle Scholar
  56. 56.
    A.L. Yu, B. Bakay, F.H. Kung, and W.L. Nyhan, Effect of 2’-deoxycoformycin on the metabolism of purines and the survival of malignant cells in patients with T cell leukemia, Cancer Res., 41: 2677 (1981).PubMedGoogle Scholar
  57. 57.
    P.P. Major, R.P. Agarwal, and D.W. Kufe, Clinical pharmacology of deoxycoformycin, Blood, 58: 91 (1981).PubMedGoogle Scholar
  58. 58.
    H.G. Prentice, K. Ganeshguru, K.F. Bradstock, A.H. Goldstone, J.F. Smyth, B. Wonke, G. Janosky, and A.V. Hoffbrand, Remission induction with adenosine deaminase inhibitor 2’-deoxycoformycin in thy-lymphoblastic leukemia, Lancet, 2: 170 (1980).PubMedCrossRefGoogle Scholar
  59. 59.
    J.R. Kanofsky, D.G. Roth, J.F. Smyth, J.F. Bann, D.L. Sweet, and J.E. Uttman, Treatment of lymphoid malignancies with 2’-deoxycoformycin - a pilot study, Am. J. Clin. Oncol., 5: 179 (1982).CrossRefGoogle Scholar
  60. 60.
    D.P. Gray, M.R. Grever, M.F.E. Slaw, M.S. Coleman, and S.P. Balcerzak, 2’-Deoxycoformycin and ara-A in the treatment of refractory acute myelocytic leukemia, Cancer Treatment Reports, 66: 253 (1982).PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • P. S. Sarin
    • 1
  • A. Thornton
    • 1
  • D. Sun
    • 1
  1. 1.Laboratory of Tumor Cell BiologyNational Cancer InstituteBethesdaUSA

Personalised recommendations